In a report released today, Matthew Weston from UBS maintained a Hold rating on Roche Holding AG (RHHVF – Research Report), with a price target of CHF270.00. The company’s shares closed yesterday at ...

And then the third speaker will be Margherita Carboni, indication Lead, Neurology and Clinical Development Lead in Neurology, Endocrinology and OB/GYN at Roche Diagnostics. She will provide us an ...

Roche's Q3 sales rose 9% year over year, reaching 15.14 billion Swiss francs (~$17.5 billion). Ocrevus sales increased 11% to 1.69 billion Swiss francs, while Vabysmo surged 59%. On Wednesday ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

On Wednesday, Roche Holdings AG (OTC:RHHBY) released its third-quarter sales report. Sales increased 9% year over year to 15.14 billion Swiss francs (~$17.5 billion). The company’s ...

Basel, 05 November 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 40 abstracts across nine blood disorders at the 66th American Society of Hematology (ASH) ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...